Asia Pacific Cervical Cancer Diagnostic Market Size, Share & Industry Trends Analysis Report By Type (Pap Smear Tests, Colposcopy Tests, HPV Test, Biopsy & ECC), By Age Group (20 to 40 years, and Above 40 years), By Country and Growth Forecast, 2023 - 2029

The Asia Pacific Cervical Cancer Diagnostic Market should witness market growth of 5.2% CAGR during the forecast period (2023-2029).

The prevalence of cervical cancer around the region is rising, which has increased the demand for diagnostic procedures like colposcopy and pelvic exams to provide doctors with a better picture of the abnormal tissues. In addition, women with cervical cancer symptoms and indicators can receive assistance from diagnostic facilities to undergo various diagnostic tests, including pap and HPV testing. The increased use of some of the most cutting-edge methods for cervical cancer diagnosis in these facilities will also accelerate the market's growth.

Favorable government initiatives for cervical cancer prevention, the rising incidence of cervical cancer, rising awareness of early detection, and strong R&D from major players in cervical cancer diagnosis and drugs are the main drivers of the market growth. Organizations are starting training programs for gynecologists and nurses to identify cervical cancer cases at an early stage. These initiatives aid in the early detection and treatment of cervical cancer, which is beneficial for market expansion. The market is also anticipated to rise as more effective combination medications and tests are introduced.

Cervical cancer comprised 18.3% (123,907) of new cases and 9.4% of all cancer cases in India in 2020. It continues to be one of the more prevalent malignancies in India and is the main reason women die from cancer in low- and middle-income countries like India. Cervical cancer is the second biggest cause of cancer deaths for women in 12 Indian states, even though the age-standardized incidence rate declined significantly by 39.7% (95% UI 265-57.3) between 1990 and 2016. Hence with the rising prevalence of cervical cancer, the utilization of various diagnostics will surge, boosting the market growth in the APAC region.

The China market dominated the Asia Pacific Cervical Cancer Diagnostic Market by Country in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $775.5 Million by 2029. The Japan market is exhibiting a CAGR of 4.6% during (2023-2029). Additionally, The India market would showcase a CAGR of 5.9% during (2023-2029).

Based on Type, the market is segmented into Pap Smear Tests, Colposcopy Tests, HPV Test, Biopsy & ECC, and Others. Based on Age Group, the market is segmented into 20 to 40 years, and Above 40 years. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Becton, Dickinson and Company, Carl Zeiss AG, CooperSurgical, Inc. (The Cooper Companies, Inc.), DYSIS Medical, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., Qiagen N.V., Siemens Healthineers AG (Siemens AG) and Thermo Fisher Scientific, Inc.

Scope of the Study

By Type

• Pap Smear Tests
• Colposcopy Tests
• HPV Test
• Biopsy & ECC
• Others

By Age Group

• 20 to 40 years
• Above 40 years

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• Abbott Laboratories
• Becton, Dickinson and Company
• Carl Zeiss AG
• CooperSurgical, Inc. (The Cooper Companies, Inc.)
• DYSIS Medical, Inc.
• F.Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Qiagen N.V.
• Siemens Healthineers AG (Siemens AG)
• Thermo Fisher Scientific, Inc.

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free